COEUR D'ALENE, Idaho, Oct 29 -- NightHawk Radiology Holdings announced Wednesday financial results for its third quarter ended Sept. 30.
The following are third quarter 2008 highlights:
"Considering the modest sequential increase in scan volume and revenue, we were able to increase adjusted earnings sequentially by 13% through improved productivity and prudently focusing on our costs," said Dr. Paul Berger, chair and CEO. "Our overall financial position remains very strong with $55.2 million in cash on hand and record cash flow from operations of $9.6 million during the third quarter and $22.9 million for the first nine months of 2008. We also saw encouraging results from our initiatives focused on improving our customer service and sales execution.
"In light of the lower than expected volumes we are seeing and the highly uncertain economic outlook, we are revising our full-year outlook and now expect full-year revenues to be in the range of $165 to $168 million and adjusted earnings per share of $0.64 to $0.67. However, I am confident that the solutions and value we provide to our customers remain a solid proposition and position us well for future growth."
The third quarter 2008 conference call was held Oct. 29. A live webcast of the conference call, as well as a replay, will be available online on the company’s website.
Participants can also access the call by dialing 800-257-2182 (or 303-262-2175 for international callers). A replay of the call will be available approximately two hours after the conclusion of the call and will remain available until midnight (EDT) on Thursday Nov. 20. To access the replay, dial 800-405-2236 or 303-590-3000 (for international callers) and enter the conference ID number: 11121223.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.